A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In adolescents with obesity, liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks compared to 0.3% with placebo, with early treatment response predicting long-term effectiveness.39”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [39]
In the citing paper
“but modest reduction in main CVD factors over 56 weeks of treatment.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“In a key RCT, there were notable reductions in BMI SDS and higher percentages of participants achieving ≥ 5% and ≥ 10% Weight loss compared to placebo and the BMI standard-deviation score at week 56 (estimated difference, − 0.22; 95% confidence interval [CI], − 0.37 to − 0.08; P = 0.002) [112]”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“Approved by FDA/EMA from age 6.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“The liraglutidetreated group demonstrated a placebo-subtracted weight reduction of 5% (29).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [29]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Establishing a standard definition for child overweight and obesity worldwide: international survey
Cole, T. J. (2000) · BMJ · doi:10.1136/bmj.320.7244.1240 · Cited by 16,480
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Freedman, D. S., Mei, Z., Srinivasan, S. R., Berenson, G. S., & Dietz, W. H. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.042 · Cited by 1,562
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Research works printed but not linked: 1
- Frelut M-L De Filippo G. Drug treatment of child and adolescent obesity. In: Frelut M-L ed. ECOG eBook on child and adolescent obesity. 2015 (https://ebook.ecog-obesity.eu/chapter-treatment/drug-treatment-of-child-and-adolescent-obesity/).
Cited by
Items 101–200 of 720
Prediabetes in Adolescents: Prevalence, Management and Diabetes Prevention Strategies
Esquivel-Zuniga, R., & DeBoer, M. D. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s284401 · Cited by 54
“Nevertheless, after the 12-week run-in period, there were no substantial differences in blood pressure, lipid abnormalities, fasting glucose levels, or HbA1c.78 Even though the FDA approved liraglutide in 2019 for management of T2DM in children greater than 10 years of age, there is a lack of data of its use in pediat…”
BackgroundInfluentialESI Clinical Practice Guidelines for the Evaluation and Management of Obesity In India
Madhu, S., Kapoor, N., Das, S., Nishant, R., & Sanjay, K. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.356236 · Cited by 57
“[93] Liraglutide has shown reduction in BMI when used in obese adolescents in addition to lifestyle intervention.[94] In a small study, liraglutide showed reduction in weight, glycemic parameters and blood pressure in Indian adolescents.”
BackgroundNutrition and Obesity in the Pathogenesis of Youth-Onset Type 1 Diabetes and Its Complications
March, C. A., BECKER, D. J., & Libman, I. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.622901 · Cited by 53
Zhou, R., Lin, C., Cheng, Y., Zhuo, X., Li, Q., Xu, W., Zhao, L., & Yang, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.600175 · Cited by 48
A 2021 Update on the Use of Liraglutide in the Modern Treatment of ‘Diabesity’: A Narrative Review
Tilinca, M. C., Tiuca, R. A., Burlacu, A., & Varga, A. (2021) · Medicina · doi:10.3390/medicina57070669 · Cited by 43
Long-term Outcomes Following Adolescent Metabolic and Bariatric Surgery
Beamish, A. J., Harper, E. R., Järvholm, K., Janson, A., & Olbers, T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad155 · Cited by 44
Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents
Lim, F., Bellows, B. K., Tan, S. X., Aziz, Z., Woo Baidal, J. A., Kelly, A. S., & Hur, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.29178 · Cited by 42
Self-citationKerem, L., & Stokar, J. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.3812 · Cited by 47
Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity
Mital, S., & Nguyen, H. V. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36400 · Cited by 41
Kotecha, P., Huang, W., Yeh, Y.-Y., Narvaez, V. M., Adirika, D., Tang, H., Bernier, A. V., WESTEN, S. C., Smith, S. M., Bian, J., et al. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.3243 · Cited by 58
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“In adolescents with obesity the study comprised a 56-week treatment period and enrolled 251 participants age 12–18 years assigned 1:1 to liraglutide or placebo, in addition to life style therapy [22].”
Liu, L., Shi, H., Shi, Y., Wang, A., Guo, N., Tao, H., & Nahata, M. C. (2024) · Pharmaceuticals · doi:10.3390/ph17070828 · Cited by 40
“The effects of semaglutide, liraglutide, and exenatide on scores for the impact of weight on quality of life—Kids (IWQOL–Kids) were measured [24,27,29].”
BackgroundMethodInfluentialMoon, S., Lee, J., Chung, H. S., Kim, Y. J., Yu, J. M., Yu, S. H., & Oh, C.-M. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.934 · Cited by 38
“36) 0 [10-13,18,19,21,23-28,31,33,34,36-38] Treatment withdrawal due to adverse events 9.”
InfluentialBenefits of physical activity on cardiometabolic diseases in obese children and adolescents
Gao, J., Lu, Y., Gokulnath, P., Vulugundam, G., Li, G., Li, J., & Xiao, J. (2022) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2022-0041 · Cited by 45
“[55] In a randomized, double-blind clinical trial, 251 adolescents aged 12–18 years were recruited to test the effect of liraglutide on obesity.[56] In addition to lifestyle therapy, 125 participants were given 3 mg liraglutide, and the others were given a placebo subcutaneously once daily.”
MethodTorbahn, G., Jones, A., Griffiths, A., Matu, J., Metzendorf, M., Ells, L. J., Gartlehner, G., Kelly, A. S., Weghuber, D., & Brown, T. J. (2024) · Pediatric Obesity · doi:10.1111/ijpo.13113 · Cited by 51
“58,60,62 This update included two trials 39,43 that reported a period of no-drug follow-up, and both reported some weight regain.”
Self-citationSteatotic Liver Disease in Pediatric Obesity and Increased Risk for Youth-Onset Type 2 Diabetes
Putri, R. R., Casswall, T., Danielsson, P., Marcus, C., & Hagman, E. (2024) · Diabetes Care · doi:10.2337/dc24-1236 · Cited by 48
Self-citationKang, S., Kang, S. M., Choi, J. H., Ko, S., Koo, B. K., Kwon, H.-S., Kim, M. K., Kim, S. Y., Kim, S., Kim, Y., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0469 · Cited by 85
Messiah, S. E., Xie, L., Atem, F., Mathew, M. S., Qureshi, F., Schneider, B. E., & Cruz-Munoz, N. F. D. L. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004493 · Cited by 37
Exogenous Bioactive Peptides Have a Potential Therapeutic Role in Delaying Aging in Rodent Models
Wang, J., Wu, Y., Chen, Z., Chen, Y., Lin, Q., & Liang, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031421 · Cited by 41
“speculated that liraglutide may have neuroprotective effects [46,47].”
BackgroundHu, Z., Li, W., Chen, S., Chen, D., Xu, R., Zheng, D., Yang, X., Li, S., Zhou, X., Niu, X., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2285-6 · Cited by 39
“As successfully reported and clinically used long-acting peptide drugs, liraglutide (Kelly et al., 2020) and semaglutide (Knudsen and Lau, 2019) exerted enhanced albumin-binding properties and in vitro plasma stability, which benefited from the addition of the fatty chain.”
BackgroundBeyond Weight Loss: Added Benefits Could Guide the Choice of Anti-Obesity Medications
Guglielmi, V., Bettini, S., Sbraccia, P., Busetto, L., Pellegrini, M., Yumuk, V., Colao, A. M. L., Ghoch, M. E., & Muscogiuri, G. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00502-7 · Cited by 44
Current and future state of pharmacological management of pediatric obesity
Fox, C. K., Kelly, A. S., Reilly, J. L., Theis-Mahon, N. R., & Raatz, S. J. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01465-y · Cited by 43
“The authors stated that these psychiatric events highlight the vulnerable nature of youth with obesity and the need for careful monitoring [35].”
Self-citationWestermeier, F., & Fisman, E. Z. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02608-9 · Cited by 45
“In adolescents aged 12 to 18 years, liraglutide significantly reduced the BMI compared with placebo [37], a benefit also observed with semaglutide in the same age group [38].”
Moustafa, A. F., Quigley, K. M., Wadden, T. A., Berkowitz, R. I., & Chao, A. M. (2021) · Obesity · doi:10.1002/oby.23185 · Cited by 42
“It is important to note the limited literature on medications for BE/LOC and weight loss in adults and adolescents alike, as most studies of weight- loss medications do not include data on BE/LOC (66).”
BackgroundThe effects of different bedroom light environments in the evening on adolescents
Wen, P., Tan, F., Wu, M., Cai, Q., Xu, R., Zhang, X., Wang, Y., Khan, M. S. A., Chen, W., & Hu, X. (2021) · Building and Environment · doi:10.1016/j.buildenv.2021.108321 · Cited by 35
Serbis, A., Giapros, V. I., Galli‐Τsinopoulou, A., & Siomou, E. C. (2020) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2020.0076 · Cited by 45
“54 In adolescents with extreme obesity and co-morbidities that do not respond to intensive lifestyle interventions or medical treatment, bariatric surgery can be considered with really promising results.”
Wen, Q., Fang, S., Liang, Y., Tian, Y., Chen, Y., Yuan, J., & Qiu, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156521 · Cited by 39
“Consistent with other GLP-1RAs such as liraglutide and semaglutide (22, 23), beinaglutide also reduces body weight by”
BackgroundGlucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Son, J. W., & Lim, S. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1940 · Cited by 33
Chu, J., Zhang, H., Wu, Y. F., Huang, Y., Zhu, T., Zhou, Z., & Wang, H. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103464 · Cited by 45
Treating the Chronic Disease of Obesity
Gossmann, M., Butsch, W. S., & Jastreboff, A. M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.005 · Cited by 33
Bensignor, M. O., Bramante, C. T., Bomberg, E. M., Fox, C. K., Hale, P. M., Kelly, A. S., Mamadi, R., Prabhu, N., Harder-Lauridsen, N. M., & Gross, A. C. (2023) · Pediatric Obesity · doi:10.1111/ijpo.13061 · Cited by 64
“1%, respectively, with placebo).(11) Similar findings were observed in the adult SCALE Obesity and Prediabetes trial, in which 63.”
BackgroundMethodResultInfluentialSelf-citationBorzutzky, C., King, E. C., Fox, C. K., Stratbucker, W., Tucker, J. M., Yee, J. K., Kumar, S., Cuda, S. E., Sweeney, B. R., Kirk, S., et al. (2020) · Pediatric Obesity · doi:10.1111/ijpo.12701 · Cited by 37
“Hispanic 2477 (31) 741 (30) 896 (36) 840 (34) 1736 (70)”
Obesity in children and adolescents: Overview of the diagnosis and management
Tung, J. Y., Poon, G. W.-K., Du, J., & Wong, K. K. Y. (2023) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.58 · Cited by 41
“22 than placebo.(64) In a recent meta‐analysis, liraglutide was shown to have a higher probability of leading to clinically significant weight loss compared with metformin, orlistat, exenatide, and topiramate.”
BackgroundCurrent Perspectives on Management of Type 2 Diabetes in Youth
Singhal, S., & Kumar, S. (2021) · Children · doi:10.3390/children8010037 · Cited by 36
Public health interventions against childhood obesity in China
Yuan, C., Dong, Y., Chen, H., Ma, L., Jia, L., Luo, J., Liu, Q., Hu, Y., Ma, J., & Song, Y. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(24)00245-7 · Cited by 36
GLP-1 Receptor Agonists in Pediatric and Adolescent Obesity
Stefater‐Richards, M. A., Jhe, G., & Zhang, Y. J. (2025) · PEDIATRICS · doi:10.1542/peds.2024-068119 · Cited by 42
Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide
Voilquin, L., Danneskiold‐Samsøe, N. B., Nguyen, Q., Wiggenhorn, A. L., Zhao, M., Wang, D. C., Toomer, D. J., Lone, J. B., Wei, Y., Patel, A. N., et al. (2025) · Nature · doi:10.1038/s41586-025-08683-y · Cited by 40
Shalaby, Y. M., Aidaros, A. A., Valappil, A., Ali, B. R., & Akawi, N. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.816301 · Cited by 43
Dagpo, T., Nolan, C. J., & Delghingaro‐Augusto, V. (2020) · Cells · doi:10.3390/cells9071596 · Cited by 35
Tilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
The Spectrum of the Prader–Willi-like Pheno- and Genotype: A Review of the Literature
Juriaans, A. F., Kerkhof, G. F., & Hokken-Koelega, A. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab026 · Cited by 29
Purnell, J. Q. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.03.001 · Cited by 37
Obesity Management in Children and Adolescents
Wong, G. W., & Srivastava, G. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.03.011 · Cited by 38
Khadilkar, V. V., Shah, N. B., Harish, R., Ayyavoo, A., Bang, A., Basu, S., Chatterjee, S., Chhatwal, J., Elizabeth, K. E., Ghate, S., et al. (2023) · Indian Pediatrics · doi:10.1007/s13312-023-3066-z · Cited by 43
“In recently published data, Liraglutide showed a modest weight loss as compared to placebo and lifestyle therapy alone (absolute change in weight was -4.50 kg [95% CI -7.17 to - 1.84] at end of 56 weeks, mean (SD) starting weight in liraglutide group being 99.3 (19.7) kg [105,106].”
InfluentialLi, H., Yu, G., Huang, Q., Yang, B., Nie, J., Liu, Y., & Tu, X. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116150 · Cited by 38
Bensignor, M. O., Bomberg, E. M., Bramante, C. T., Divyalasya, T. V. S., Hale, P. M., Ramesh, C. K., Rudser, K. D., & Kelly, A. S. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12778 · Cited by 34
“Weight was measured at site visits at screening, randomization and weeks 6, 10, 14, 20, 26, 30, 36, 42, 48 and 52; height and WC were measured at site visits at screening, randomization and weeks 14, 26 and 52.”
InfluentialSelf-citationCornejo-Estrada, A., Nieto-Rodríguez, C., León‐Figueroa, D. A., Moreno-Ramos, E., Cabanillas-Ramirez, C., & Barboza, J. J. (2023) · Children · doi:10.3390/children10020208 · Cited by 38
“, 2020) [30] was assumed to be of high-quality isk of bias.”
BackgroundMethodResultInfluential2023 Clinical Practice Guidelines for Diabetes
Moon, M. K. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.3.120 · Cited by 27
“12세 이상의 2형당뇨병 소아청소 년에서 2단계 이상의 비만(체질량지수 95백분위수의 120%) 이 동반되었을 경우, 리라글루타이드를 사용할 수 있다[18].”
Tuccinardi, D., Masi, D., Watanabe, M., Zanghi Buffi, V., De Domenico, F., Berti, S., Cipriani, V., Manco, M., Manfrini, S., & Pagotto, U. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02700-7 · Cited by 29
“…percentages of participants achieving ≥ 5% and ≥ 10% Weight loss compared to placebo and the BMI standard-deviation score at week 56 (estimated difference, − 0.22; 95% confidence interval [CI], − 0.37 to − 0.08; P = 0.002) [112], but modest reduction in main CVD factors over 56 weeks of treatment.”
InfluentialKim, T. H., Lee, K., Park, S., Cho, H., Park, J., Jo, H., Son, Y., Kim, S., Kang, J., Smith, L., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15864 · Cited by 29
“23 In a randomized controlled trial investigating liraglutide use in adolescents with obesity, incidents of suicide ideation and attempts were noted, but were considered unrelated to liraglutide due to the presence of comorbid conditions such as attention-deficit hyperactivity disorder or…”
Obesity, Cardiovascular and Neurodegenerative Diseases: Potential Common Mechanisms
Kuneš, J., Hojná, S., Mráziková, L., Montezano, A. C. I., Touyz, R. M., & Maletínská, L. (2023) · Physiological Research · doi:10.33549/physiolres.935109 · Cited by 34
Torbahn, G., Lischka, J., Brown, T. J., Ells, L. J., Kelly, A. S., Wabitsch, M., & Weghuber, D. (2024) · Clinical Endocrinology · doi:10.1111/cen.15133 · Cited by 33
Self-citationPediatric Obesity Pharmacotherapy: State of the Science, Research Gaps, and Opportunities
Armstrong, S., Eneli, I., Osganian, S. K., Wagner, B. E., Waldrop, S., & Kelly, A. S. (2024) · PEDIATRICS · doi:10.1542/peds.2024-067858 · Cited by 31
Self-citationTreatment of Hypothalamic Obesity With GLP-1 Analogs
Dimitri, P., & Roth, C. L. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae200 · Cited by 25
Pharmacotherapy in Childhood Obesity
Kühnen, P., Biebermann, H., & Wiegand, S. (2021) · Hormone Research in Paediatrics · doi:10.1159/000518432 · Cited by 32
Anastasiou, I. A., Argyrakopoulou, G., Dalamaga, Μ., & Kokkinos, A. D. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00623-1 · Cited by 29
“Efficacy was predicted by early response to treatment [115].”
InfluentialVacurova, E., Trnovská, J., Svoboda, P., Škop, V., Novosadová, V., Reguera, D. P., Petrezsélyová, S., Piavaux, B. J. A., Endaya, B., Špoutil, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29486-z · Cited by 28
The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon
Spezani, R., & Mandarim-de-Lacerda, C. A. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120188 · Cited by 23
Peptide GLP-1 receptor agonists: From injection to oral delivery strategies
Ke, Z., Ma, Q., Ye, X., Wang, Y., Jin, Y., Zhao, X., & Su, Z. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116471 · Cited by 28
Medical treatment of weight loss in children and adolescents with obesity
Calcaterra, V., Rossi, V., Mari, A., Casini, F., Bergamaschi, F., Zuccotti, G., & Fabiano, V. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106471 · Cited by 26
Semaglutide treatment for children with obesity: an observational study
van Boxel, E.-J., Rahman, S., Lai, K., Boulos, N., & Davis, N. L. (2024) · Archives of Disease in Childhood · doi:10.1136/archdischild-2023-326687 · Cited by 30
Stefano, R. D., Rindi, L. V., Baldini, V., Rossi, R., Pacitti, F., Jannini, E. A., & Rossi, A. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103238 · Cited by 27
Kidney Considerations in Pediatric Obesity
Sawyer, A., Zeitler, E. M., Trachtman, H., & Bjornstad, P. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00522-3 · Cited by 25
“In the adolescent population, liraglutide is superior to placebo for reduction of BMI [99].”
BackgroundLiraglutide-Induced Hepatotoxicity
Maor, Y., Ergaz, D., Malnick, S. D. H., Melzer, E., & Neuman, M. G. (2021) · Biomedicines · doi:10.3390/biomedicines9020106 · Cited by 22
“To date, there has been only one reported case of liraglutide-induced autoimmune hepatitis [11].”
BackgroundType 2 Diabetes Mellitus in Childhood and Adolescence
Koren, D., & Levitsky, L. L. (2021) · Pediatrics in Review · doi:10.1542/pir.2019-0236 · Cited by 25
Ng, V. W. W., Gerard, G., Koh, J. J. K., Loke, K. Y., Lee, Y. S., & Ng, N. B. H. (2024) · Clinical Obesity · doi:10.1111/cob.12642 · Cited by 21
“10,11 GLP-1 is a gut incretin secreted from intestinal neuroendocrine L-cells in response to food intake.”
BackgroundRomariz, L. M., de Melo, A. A. C., Finnegan, E. A., de Mesquita, Y. L. L., & Janovsky, C. C. P. S. (2025) · Pediatric Research · doi:10.1038/s41390-025-04228-1 · Cited by 29
“Abbreviations: CI con fi dence interval, RR risk ratio, GLP1RA glucagon-like peptide 1 receptor agonist.”
Hagman, E., Johansson, L., Kollin, C., Marcus, E., Drangel, A., Marcus, L., Marcus, C., & Danielsson, P. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01146-8 · Cited by 29
“Hence, weight regain, which is common in all types of treatment [29, 30], may be prevented to a large extent and a continuous relative weight loss could be achieved during the entire treatment year (Supplementary Fig.”
Self-citationGlucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
Berman, C., Vidmar, A. P., & Chao, L. C. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.1.38 · Cited by 28
“002).(68) A reduction in BMI of at least 5% was observed in 43.”
Comprehensive transition of care for polycystic ovary syndrome from adolescence to adulthood
Simon, S. L., Phimphasone‐Brady, P., McKenney, K. M., Gulley, L. D., Bonny, A. E., Moore, J. M., Torres-Zegarra, C., & Cree‐Green, M. (2024) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(24)00019-1 · Cited by 30
Sedenho‐Prado, L. G., Yugar, L. B. T., Whitaker, A. R., Martins, M., Jesus, D. C., Ferreira, I. M. C. D. S., Silva, C. A. M., Nadruz, W., Cercato, C., & Sposito, A. C. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01790-w · Cited by 29
“No studies were identi fi ed as having a high risk of bias.”
InfluentialGill, L. A., & Mackey, S. (2021) · Journal of Women s Health · doi:10.1089/jwh.2020.8683 · Cited by 23
Herouvi, D., Paltoglou, G., Soldatou, A., Kalpia, C., Karanasios, S., & Karavanaki, K. (2023) · Children · doi:10.3390/children10071230 · Cited by 32
Chetty, A. K., Rafi, E., Bellini, N. J., Buchholz, N., & Isaacs, D. M. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.12.010 · Cited by 23
Shamim, M. A., Patil, A., Amin, U., Roy, T., Tiwari, K., Husain, N., Kumar, J., Chenchula, S., Rao, P. P., Ganesh, V., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15777 · Cited by 26
“17,21 Semaglutide has emerged as a promising drug among GLP-1RAs due partly to its availability of oral formulation.”
InfluentialPharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
Jaoudeh, R. A. R. A., Hartmann, P., Olson, O., Gupta, O. T., Kumar, S., Ibrahim, S. H., Fawaz, R. L., Aqul, A. A., & Hassan, S. M. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12402 · Cited by 23
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?
Strong, J., & Driscoll, M. S. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00911-x · Cited by 22
“…approved in December 2020 for weight management of pediatric patients aged 12 years or older who are at least 60 kg and with elevated BMI for their age and sex, after a significant reduction in BMI compared with placebo was observed in a double blind randomized controlled trial (RCT) [30, 31].”
Abawi, O., Koster, E. C., Welling, M. S., Boeters, S. C. M., van Rossum, E. F. C., van Haelst, M. M., van der Voorn, B., de Groot, C. J., & van den Akker, E. L. T. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.862817 · Cited by 22
Cuda, S. E., Censani, M., Kharofa, R. Y., O’Hara, V. M., Conroy, R., Williams, D. R., Paisley, J., Browne, A. F., Karjoo, S., & Browne, N. T. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100048 · Cited by 22
“The mechanism of action (MOA) of liraglutide is that it mimics the action of the GLP-1 incretin, which stimulates post-prandial insulin secretion, reduces glucagon secretion, delays gastric emptying, and induces weight loss through reduction of hunger and food intake [36 – 38].”
BackgroundPharmacological Treatments and Natural Biocompounds in Weight Management
Gasmi, A., Mujawdiya, P. K., Nehaoua, A., Shanaida, M., Semenova, Y. M., Piscopo, S., Menzel, A., Voloshyn, V., Voloshyn, O., Shanaida, V., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020212 · Cited by 24
“However, more participants taking Liraglutide displayed adverse gastrointestinal effects, leading to the trial treatment discontinuation [42].”
BackgroundNew Insights into the Use of Liraglutide—Impact on Cardiovascular Risk and Microvascular Outcomes
Wronka, M., Krzemińska, J., Młynarska, E., Rysz, J., & Franczyk, B. (2023) · Biomedicines · doi:10.3390/biomedicines11041159 · Cited by 25
Yan, Y., Gong, Y., Jiang, M., Gao, Y., Guo, S., Huo, J., Zhao, Z., & Li, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1170127 · Cited by 20
“0mg liraglutide was proven to have a greater impact on body mass index (BMI) reduction compared with placebo (14).”
BackgroundThe role of incretin receptor agonists in the treatment of obesity
Forst, T. M., Block, C. E. M. D., Prato, S. D., Armani, S., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15796 · Cited by 22
Jebeile, H., Baur, L. A., Kwok, C., Alexander, S., Brown, J. J., Collins, C. E., Cowell, C. T. C. T., Day, K., Garnett, S. P., Gow, M. L., et al. (2024) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2024.2851 · Cited by 27
Effectiveness of a Weight Loss Program Using Digital Health in Adolescents and Preadolescents
Lei, S., Medina‐Inojosa, J. R., Kumar, S., Lee, A. T., Scott, C. G., Lerman, A., Lerman, L. O., Senecal, C., Lin, W., Zhang, X., et al. (2021) · Childhood Obesity · doi:10.1089/chi.2020.0317 · Cited by 22
“39 It was reported that participants achieved reduction on body weight of 4.5 kg, BMI of 3.13 kg/m 2 , and BMI z-score of 0.22 at 56 weeks using liraglutide.”
InfluentialJiao, X., Peng, P., Zhang, Q., & Shen, Y. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01319-x · Cited by 24
“Beyond its anti-diabetic effects, GLP-1RAs has demonstrated therapeutic potential for conditions such as obesity [39–41], cardio-vascular disease [24, 42, 43], kidney disease [44, 45], and other complications [46].”
Yang, S., Xin, S., Ju, R., & Zang, P. (2025) · PLoS ONE · doi:10.1371/journal.pone.0314787 · Cited by 28
“In Kelly 2020 [21], researchers included individuals with type 2 diabetes, and stratified blocked randomization was conducted based on blood glucose status (average blood glucose vs. pre-diabetes or type 2 diabetes), with mean fasting blood glucose at baseline of 94.3 mg/dl (SD 9.5).”
InfluentialUnderstanding peptide hormones: from precursor proteins to bioactive molecules
Voilquin, L., Wiggenhorn, A. L., & Svensson, K. J. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.03.014 · Cited by 20
Clinical approaches to minimize iatrogenic weight gain in children and adolescents
Sweeney, B. R., Kelly, A. S., Giovanni, C. B. S., Kelsey, M. M., & Skelton, J. A. (2020) · Clinical Obesity · doi:10.1111/cob.12417 · Cited by 18
“Some additional evidence supports metabolic/bariatric surgery for children 10 and older with severe obesity,(1) and use of adjunctive medications, with minimal data on safety and efficacy in paediatrics.(2,3) Effective obesity treatment is”
BackgroundSelf-citationAtualizações sobre os medicamentos da Diretriz Brasileira de Obesidade: uma revisão de literatura
Marcon, G. M., Sanches, A. C. C., & Virtuoso, S. (2022) · Research Society and Development · doi:10.33448/rsd-v11i4.27139 · Cited by 34
Clinical review: Guide to pharmacological management in pediatric obesity medicine
O’Hara, V. M., Cuda, S. E., Kharofa, R. Y., Censani, M., Conroy, R., & Browne, N. T. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100066 · Cited by 23
“Simultaneous use of topiramate and phentermine has a synergic effect [93].”
InfluentialKang, E., Hong, Y. H., Kim, J. H., Chung, S., Kim, K. K., Haam, J.-H., Kim, B. T., Kim, E. M., Park, J. H., Rhee, S. Y., et al. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23060 · Cited by 26
Glucagon-like peptide receptor agonists and risk for depression
Tagliapietra, G. A., Cantrell, M. A., & Lund, B. C. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.05.005 · Cited by 21
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
“[16] 15] Individuals’ responses to Liraglutide for weight management exhibit considerable variation.”
Clinical guidelines «Obesity in children»
Vasyukova, O. V., Okorokov, P. L., Malievskiy, O. A., Неймарк, А. Е., Zorin, E. A., Yashkov, Y. I., Burmitskaya, Y. V., Kopytina, D. A., Bezlepkina, O. B., & Peterkova, V. A. (2024) · Obesity and metabolism · doi:10.14341/omet13194 · Cited by 24
Recent progress in the pharmacotherapy for obesity
Lu, J., Liu, P., Cai, M., Lv, T., Zhang, M., Yin, K., Cheng, J., & Zhang, G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177850 · Cited by 17
Liraglutide pharmacokinetics and exposure‐response in adolescents with obesity
Petri, K. C. C., Hale, P. M., Hesse, D., Rathor, N., & Mastrandrea, L. D. (2021) · Pediatric Obesity · doi:10.1111/ijpo.12799 · Cited by 22
“002).(23) A previous population pharmacokinetic analysis performed with liraglutide using adult data from the 56-week phase 3a SCALE Obesity and Prediabetes trial (1839)(24) and SCALE Diabetes trial (1922)(25) trials found that sex and body weight were the only intrinsic factors that influenced the exposure (ie, the a…”
MethodSelf-citationIncretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
Rosenberg, J., Jacob, J., Desai, P., Park, J., Donovan, L., & Kim, J. Y. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21053 · Cited by 20
Drug dosing in children with obesity: a narrative updated review
Gaeta, F., Conti, V., Pepe, A., Vajro, P., Filippelli, A., & Mandato, C. (2022) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-022-01361-z · Cited by 20
“More recently it has been shown that in adolescents between 10 and 17 years of age with type 2 diabetes mellitus, chronic liraglutide is effective also for BMI reduction between 12 and 17 years of age with obesity and at the end of a 56-week treatment observed a reduction in BMI in patients treated with liraglutide co…”
BackgroundMetabolic Syndrome in Children and Adolescents
Chung, L. Y., & Rhie, Y. (2022) · Ewha Medical Journal · doi:10.12771/emj.2022.e13 · Cited by 28
“Exenatide [46] GLP-1 agonist T2DM in adults <18 years of age for obesity (polygenic with the presence of diabetes, hypothalamic, syndromic) Bloating, diarrhea, flatulence”
Background
Metadata
- Authors
- Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); Novo Nordisk, Søborg, Denmark (P.A.); Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Plainsboro, NJ (P.M.H.); the Division of Pediatrics, Department of Clinical Science Intervention and Technology,...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-28
- Volume
- 382
- Issue
- 22
- Pages
- 2117-2128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013213902
- Cited by
- 723
- References
- 34
- Citations by year
- 2026: 133 · 2025: 143 · 2024: 149 · 2023: 109 · 2022: 80 · 2021: 80 · 2020: 26
- FWCI
- 44.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, adolescent obesity, childhood obesity, weight management, GLP-1 receptor agonists, lifestyle therapy, body mass index, gastrointestinal adverse effects, drug discontinuation, long-term weight maintenance, drug efficacy
- MeSH terms
- Liraglutide, Healthy Lifestyle, Adolescent, Blood Glucose, Child, Combined Modality Therapy, Double-Blind Method, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Injections, Subcutaneous, Male, Body Mass Index, Incretins, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.